600276 恒瑞醫藥
按盤價 
66.020 +1.040 (+1.600%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 15,761,194 | 15.88% | 27,984,605 | 22,819,785 | 21,275,271 | 25,905,526 | |
| 減：營業總成本 | 10,900,174 | 11.73% | 21,008,001 | 18,214,153 | 17,747,084 | 21,792,969 | |
| 其中:營業成本 | 2,114,962 | 12.90% | 3,848,177 | 3,525,248 | 3,486,639 | 3,741,799 | |
| 財務費用 | (241,036) | -36.94% | (572,732) | (478,390) | (470,867) | (337,956) | |
| 資產減值損失 | (9,444) | -159.71% | (32,538) | (107,217) | (146,684) | (13,861) | |
| 公允價值變動收益 | 111,264 | 1,375.22% | 108,631 | (58,257) | 76,503 | 36,233 | |
| 投資收益 | (22,158) | 37.28% | 4,279 | (49,157) | 387,365 | 213,434 | |
| 其中：對聯營企業和合營企業的投資收益 | (41,467) | 20.62% | (21,581) | (72,696) | (62,996) | (6,940) | |
| 營業利潤 | 5,158,893 | 29.47% | 7,490,632 | 4,909,905 | 4,111,960 | 4,664,816 | |
| 利潤總額 | 5,050,934 | 34.63% | 7,169,690 | 4,667,110 | 3,968,492 | 4,466,309 | |
| 減：所得稅費用 | 596,264 | 84.33% | 832,695 | 389,289 | 153,351 | (17,718) | |
| 淨利潤 | 4,454,671 | 29.94% | 6,336,995 | 4,277,821 | 3,815,142 | 4,484,027 | |
| 減：非控股權益 | 4,564 | -226.23% | 468 | (24,615) | (91,233) | (46,191) | |
| 股東淨利潤 | 4,450,106 | 29.67% | 6,336,527 | 4,302,436 | 3,906,375 | 4,530,218 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.700 | 29.63% | 1.000 | 0.680 | 0.610 | 0.710 | |
| 每股派息 (元) * | -- | -- | 0.200 | 0.200 | 0.160 | 0.160 | |
| 每股淨資產 (元) * | 8.809 | 31.83% | 7.136 | 6.344 | 5.929 | 5.473 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 25/08/2025 14:12 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
